Drug safety evaluation of alemtuzumab for multiple sclerosis
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14740338.2014.928691
Reference55 articles.
1. Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
2. Interferon-? therapy reduces CD4+and CD8+T-cell reactivity in multiple sclerosis
3. Multiple sclerosis: Comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
4. Distinct Properties of Circulating CD8+ T Cells in FTY720-Treated Patients With Multiple Sclerosis
5. Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Colitis in ocrelizumab-treated patients: The dilemma of causation versus association in immune-mediated iatrogenicity;Multiple Sclerosis Journal;2023-09
2. Long-term drug treatment in multiple sclerosis: safety success and concerns;Expert Opinion on Drug Safety;2020-08-13
3. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis;Multiple Sclerosis and Related Disorders;2019-04
4. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers;Therapeutic Advances in Neurological Disorders;2019-01
5. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison;Journal of Medical Economics;2018-11-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3